- /
- Supported exchanges
- / US
- / ADXN.NASDAQ
Addex Therapeutics Ltd (ADXN NASDAQ) stock market data APIs
Addex Therapeutics Ltd Financial Data Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Addex Therapeutics Ltd data using free add-ons & libraries
Get Addex Therapeutics Ltd Fundamental Data
Addex Therapeutics Ltd Fundamental data includes:
- Net Revenue: 173 K
- EBITDA: -2 814 174
- Earnings Per Share: -9
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Addex Therapeutics Ltd News
New
Addex Convenes Annual General Meeting 2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of...
Addex Reports Neurosterix On Track To Complete Phase 1 Trial For Schizophrenia Drug NTX-253
(RTTNews) - Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, announced on Wednesday that the Phase 1 trial for NTX-253 in treating schizophrenia, developed by spun-out compa...
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a po...
Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceu...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.